"however, in the event of any such exercise, we will receive up to a 50% equity interest in H Pharmaceuticals K/S (formerly Hedrin Pharmaceuticals K/S), a Danish limited partnership, of which we and the selling securityholder are partners, of the 52.38% equity interest which is currently held by the selling securityholder. We also will receive the proceeds of any cash exercise of the warrant."
First off it sounds like a conditional statement. As I said before, warrants are not shares, only possible shares, and it says they get a 50% interest in return if the warrants are exercised.....Sounds to me like like two partners swapping stock for stock. Anyway, I still think the market cap even if it is 200,000,000 shares is way too low now.
I still do not see any sellers. For a penny stock with so many shares issued, why is the daily volume so low, even zero on some days! No one is really selling! Any real buying volume on news is going to send this one up.
I will try and read the actual filing this weekend, if I have the time.
Thanks for the HEADS up, and details, as I missed it!!!! I do have a order in for more shares if it goes any lower. I have bought shares at .02 all the way .09, so if it goes any lower again, I will not miss the opportunity to add!!!!
One last thought, aren't some or all of those shares and warrants being listed for the new stock holders previously restricted shares that were issued for the recent merger, and thus not new shares, but simply existing shares being listed and converted to unrestricted shares?
Recent TGTX News
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/15/2024 12:45:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/12/2024 10:02:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/12/2024 10:01:39 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 11/12/2024 05:49:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/12/2024 04:36:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/12/2024 04:12:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2024 09:33:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/05/2024 06:42:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2024 12:19:19 PM
- TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance • GlobeNewswire Inc. • 11/04/2024 12:00:00 PM
- TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update • GlobeNewswire Inc. • 11/01/2024 12:06:02 PM
- New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis • GlobeNewswire Inc. • 09/18/2024 11:15:00 AM
- New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment • GlobeNewswire Inc. • 09/18/2024 11:00:00 AM
- Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 • PR Newswire (US) • 09/06/2024 10:43:00 PM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting • GlobeNewswire Inc. • 09/05/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:03:55 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 08/09/2024 08:01:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 11:08:39 AM
- TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance • GlobeNewswire Inc. • 08/06/2024 11:00:00 AM
- TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update • GlobeNewswire Inc. • 08/05/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:48:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 07:08:53 PM
- Form PX14A6G - Notice of exempt solicitation submitted by non-management • Edgar (US Regulatory) • 06/10/2024 03:23:35 PM
- TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/07/2024 11:50:00 AM
- TG Therapeutics to Participate in the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 06/03/2024 11:30:00 AM
FEATURED North Bay Resources Announces Production of Gold Concentrate and Refinery Shipment at Bishop Gold Mill, California • Nov 18, 2024 9:00 AM
One World Products Sets New Standards in Sustainability With Strategic Hemp Innovations • OWPC • Nov 18, 2024 7:54 AM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM